Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436265 | 1.00 | HCAR2 (0.37) | HCAR2MMEDYRK1AGSK3BIRAK4 | |
| SCHEMBL3436264 | 1.00 | HCAR2 (0.37) | HCAR2MMEDYRK1AGSK3BIRAK4 | |
| SCHEMBL12984738 | 0.93 | HCAR2 (0.41) | HCAR2MMEDYRK1AGSK3BIRAK4 | |
| SCHEMBL3547638 | 0.83 | IRAK4 (0.39) | HCAR2MMEDYRK1AGSK3BIRAK4 | |
| SCHEMBL2079741 | 0.83 | CHRM2 (0.37) | DYRK1AGSK3BIRAK4BACE1PRKCB | |
| SCHEMBL3436252 | 0.83 | CHRM2 (0.37) | DYRK1AGSK3BIRAK4BACE1PRKCB | |
| SCHEMBL10068463 | 0.79 | DYRK1A (0.39) | DYRK1AGSK3BIRAK4 | |
| SCHEMBL10037330 | 0.79 | DYRK1A (0.37) | DYRK1AGSK3BIRAK4PTGER2PTGIR | |
| SCHEMBL1807234 | 0.78 | NPC1 (0.44) | DYRK1AGSK3B | |
| SCHEMBL12467250 | 0.77 | ALDH1A1 (0.45) | MMEDYRK1AGSK3BIRAK4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HCAR2 107/4885MME 2086/4885DYRK1A 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.